Please try another search
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Wayne Klohs | - | 2016 | Member of Scientific Advisory Board |
Laurie D. Stelzer | 56 | 2023 | Independent Director |
Daniel Douglas Von Hoff | 76 | 2016 | Member of Scientific Advisory Board |
Keith T. Flaherty | 53 | 2016 | Member of Scientific Advisory Board |
Matthew Vander Heiden | - | 2016 | Member of Scientific Advisory Board |
Arthur E. Frankel | - | 2016 | Member of Scientific Advisory Board |
Tomas Kiselak | 37 | 2023 | Independent Director |
Michael Thomas Henderson | 34 | 2023 | Independent Director |
Peter Evan Harwin | 38 | 2023 | Independent Director |
Cameron Turtle | 34 | 2023 | CEO & Director |
Mark C. McKenna | 48 | 2024 | Independent Director |
Jeffrey W. Albers | 53 | 2023 | Independent Chairman of the Board |
Sandra Milligan | 60 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review